loading page

Polystyrene nanoparticles-mediated astragalus polysaccharides down-regulate IL-2 through TLR4/MyD88/NF-κB pathway in lung cancer
  • +1
  • Bangyun Tan,
  • Zhiwu Liu,
  • Xiaoying Xu,
  • Liqiong Yao
Bangyun Tan
Lanzhou University First Hospital

Corresponding Author:[email protected]

Author Profile
Zhiwu Liu
Lanzhou University First Hospital
Author Profile
Xiaoying Xu
Lanzhou University First Hospital
Author Profile
Liqiong Yao
Lanzhou University First Hospital
Author Profile

Abstract

Immune escape and immunosuppression are the main reasons that affect the efficacy of lung cancer treatment. This study mainly explored the mechanism of polystyrene nanoparticles-mediated astragalus polysaccharides (APS-PSNPs) in improving immune function of mice with lung cancer. APS-PSNPs were constructed and a lung cancer mouse model was established to observe tumor volume and mass, and pathological changes by HE staining. Levels of TNF-a/IFN-γ/IL-2/IL-6 in mouse spleen tissue were detected by ELISA, the lymphocyte CD3+, CD4+, CD8+ apoptosis levels were tested along with analysis of the expression of TLR4, MyD88, and NF-κB. (1) APS-PSNPs were successfully constructed. (2) APS-PSNPs had a good tumor suppressor effect on lung cancer, inhibited IL-2 expression, and improved immune function of lung cancer mice. (3) TLR4, MyD88, NF-κB levels in lung cancer mice were upregulated, and MyD88 and NF-κB levels decreased after inhibiting TLR4 expression with improved pathological changes of lung. (4) APS-PSNPs effectively reduced TLR4, MyD88, NF-κB levels. The levels of TNF-a/IFN-γ/IL-2/IL-6 decreased in APS-PSNPs+TAK-242 group, the apoptosis of spleen lymphocyte subsets CD3+, CD4+, CD8+ was significantly weakened, and the degree of fibrosis of lung tumor tissue was significantly lower. APS-PSNPs, with good anti-lung cancer value, can improve immune function, inhibit lung tissue lesions, and inhibit tumor progression to a certain extent. This process is related to reducing TLR4/MyD88/NF-κB activity and down-regulating IL-2, etc.
14 Mar 2024Assigned to Editor
14 Mar 2024Submission Checks Completed
10 Apr 2024Reviewer(s) Assigned